Sugi Predict

Sugi Predict / Compounds / SCHEMBL3148016

SCHEMBL3148016

SCHEMBL3148016

CC(=O)Nc1ccc2c(c1)ncn2-c1cncc(N[C@@H](C)c2ccccc2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 2/20 0.59
▸ AURKB Q96GD4 2/20 0.59
▸ NPC1 O15118 3/20 0.57
▸ RAB9A P51151 3/20 0.57
▸ JAK3 P52333 6/20 0.49
▸ FYN P06241 2/20 0.49
▸ FLT1 P17948 2/20 0.49
▸ KDR P35968 2/20 0.49
▸ BTK Q06187 2/20 0.49
▸ STK16 O75716 1/20 0.49
▸ SRC P12931 1/20 0.49
▸ ADRA2B P18089 1/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ LCK P06239 7/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ CSF1R P07333 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17627185 1.00 AURKA (0.59) AURKAAURKBNPC1RAB9AJAK3
SCHEMBL3143104 0.93 AURKA (0.59) AURKAAURKBNPC1RAB9AJAK3
SCHEMBL3145003 0.92 AURKA (0.58) AURKAAURKBNPC1RAB9AJAK3
SCHEMBL3144080 0.90 AURKA (0.56) AURKAAURKBNPC1RAB9AJAK3
SCHEMBL3141032 0.89 AURKA (0.55) AURKAAURKBNPC1RAB9AJAK3
SCHEMBL13313168 0.89 AURKA (0.54) AURKAAURKBNPC1RAB9AJAK3
SCHEMBL3143344 0.89 AURKA (0.54) AURKAAURKBNPC1RAB9AJAK3
SCHEMBL3260763 0.88 AURKA (0.54) AURKAAURKBNPC1RAB9AJAK3
SCHEMBL3145860 0.88 CSF1R (0.57) AURKAAURKBNPC1RAB9AJAK3
SCHEMBL3138308 0.88 AURKA (0.54) AURKAAURKBNPC1RAB9AJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737143-B2 Substituted pyrazines as kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2010-06-15 — — US claimed
EP-1511742-B1 KINASE INHIBITORS CYTOPIA RES PTY LTD (AU) 2010-02-03 — — EP claimed
US-7259179-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2007-08-21 — — US claimed
US-20070161635-A1 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2007-07-12 — — US claimed
US-20070099935-A1 such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2007-05-03 — — US claimed
US-20050004140-A1 Kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2005-01-06 — — US claimed
EP-1689739-B1 AZOLE-BASED KINASE INHIBITORS YM BIOSCIENCES AUSTRALIA PTY (AU) 2016-03-30 — — EP disclosed
US-7737143-B2 Substituted pyrazines as kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2010-06-15 — — US disclosed
US-7737143-B2 Substituted pyrazines as kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2010-06-15 — — US disclosed
EP-1511742-B1 KINASE INHIBITORS CYTOPIA RES PTY LTD (AU) 2010-02-03 — — EP disclosed
EP-1511742-B1 KINASE INHIBITORS CYTOPIA RES PTY LTD (AU) 2010-02-03 — — EP disclosed
US-7598272-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2009-10-06 — — US disclosed
US-7598272-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2009-10-06 — — US disclosed
US-20070161635-A1 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2007-07-12 — — US disclosed
US-20070161635-A1 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2007-07-12 — — US disclosed
US-20070099935-A1 such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2007-05-03 — — US disclosed
US-20070099935-A1 such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2007-05-03 — — US disclosed
US-20060270687-A1 Kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2006-11-30 — — US disclosed
US-20060241112-A1 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2006-10-26 — — US disclosed
US-20050004140-A1 Kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2005-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270687-A1 Kinase inhibitors MAP3K20, MAP3K1, MAP3K19 AURKA 327/4885AURKB 349/4885NPC1 1026/4885
US-20070099935-A1 such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases PRKACA, MAP3K6, PRKDC AURKA 486/4885AURKB 837/4885NPC1 2219/4885
US-20060241112-A1 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states MAP4K2, MAP4K5, MAP4K4 AURKA 440/4885AURKB 448/4885NPC1 678/4885
US-20050004140-A1 Kinase inhibitors MAP3K20, MAP3K1, MAP3K19 AURKA 327/4885AURKB 349/4885NPC1 1026/4885
US-20070161635-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K10 AURKA 358/4885AURKB 352/4885NPC1 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.